Furthermore, via network pharmacology method and experimental verification, our study also confirmed that the anti-thrombocytopenia activity of DMAG might be mediated by activating PI3K–Akt signaling pathway, hematopoietic cell lineage, ECM-receptor interaction and platelet activation. The gene discussed is AKT1; the disease is Thrombocytopenia.